Catalent today welcomed the news from Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule charged sodium channel blockers, that its first patient has been dosed with NOC-100, an inhaled formula of its NTX-1175 small molecule candidate.

Catalent today announced that it has acquired a new manufacturing facility in Bloomington, Indiana, to create a North American center of excellence for early-phase clinical biologics formulation development and drug product fill/finish services.

Catalent today announced that George Buchman, Ph.D., Vice President, Preclinical & Process Development, will present at the World Vaccine Congress, which will take place virtually on Sept. 28 – October 1, 2020.

T-knife and Catalent today announced they have signed an agreement to provide technology transfer and CGMP clinical manufacturing of T-knife’s T1367 T-cell receptor (TCR) program.

Catalent today announced that it will present at the upcoming BioProcess International virtual conference, taking place between Sept. 21 – 25, 2020.

We are proud to announce that Rheincell has GMP certification and Manufacturing Authorization to supply clinical-grade iPSCs and thus, make a meaningful contribution to advancing cell therapies

Catalent today announced that it will lead multiple workshops and exhibit at the upcoming Global Clinical Supplies Group (GCSG) 2020 Global Virtual Conference, which takes place on Sept. 21-25, 2020.

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today welcomed the news that the company is being added to the iconic S&P 500® index published by S&P Dow Jones Indices.

Catalent today announced that it is investing $130 million to add five additional Phase 3 through commercial-scale manufacturing suites to its gene therapy campus in Harmans, Maryland.